Reference : Le melanome metastatique: un vent d'espoir porte par l'ipilimumab et le vemurafenib.
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/142665
Le melanome metastatique: un vent d'espoir porte par l'ipilimumab et le vemurafenib.
French
[en] Metastatic melanoma: some hope from ipilimumab and vemurafenib
Franchimont, Claudine mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques >]
PIERARD, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
2012
Revue Médicale de Liège
67
2
64-8
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Antibodies, Monoclonal/adverse effects/pharmacology/therapeutic use ; Antineoplastic Agents/adverse effects/pharmacology/therapeutic use ; Humans ; Indoles/adverse effects/pharmacology/therapeutic use ; Melanoma/drug therapy/pathology ; Neoplasm Metastasis ; Neoplasm Staging ; Skin Neoplasms/drug therapy/pathology ; Sulfonamides/adverse effects/pharmacology/therapeutic use ; Survival Rate ; Translational Medical Research
[en] Treating a patient with cutaneous malignant melanoma relies on the recognition of a clever stratification of the distinct stages of the disease. The histoprognostic criteria were recently revisited. In addition, translational research fueled the development of new treatments with at last increased efficacy in the metastatic stage. Such therapeutic advance improves the median overall survival for a few months. Some combined treatments could possibly boost the beneficial effects.
http://hdl.handle.net/2268/142665

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
MELANOME METASTATIQUE.pdfPublisher postprint211.5 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.